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ABSTRACT
Background. Risk of encapsulating peritoneal sclerosis (EPS) is
strongly associated with the duration of peritoneal dialysis
(PD), such that patients who have been on PD for some time
may consider elective transfer to haemodialysis to mitigate the
risk of EPS. There is a need to determine this risk to better in-
form clinical decision making, but previous studies have not
allowed for the competing risk of death.
Methods. This study included new adult PD patients in
Australia and New Zealand (ANZ; 1990–2010) or Scotland
(2000–08) followed until 2012. Age, time on PD, primary renal
disease, gender, data set and diabetic status were evaluated as
predictors at the start of PD, then at 3 and 5 years after starting
PD using ﬂexible parametric competing risks models.
Results. In 17 396 patients (16 162 ANZ, 1234 Scotland), EPS
was observed in 99 (0.57%) patients, less frequently in ANZ
patients (n¼ 65; 0.4%) than in Scottish patients (n¼ 34; 2.8%).
The estimated risk of EPS was much lower when the competing
risk of death was taken into account (1 Kaplan–Meier¼ 0.0126,
cumulative incidence function¼ 0.0054). Strong predictors of
EPS included age, primary renal disease and time on PD. The
risk of EPS was reasonably discriminated at the start of PD (C-
statistic ¼ 0.74–0.79) and this improved at 3 and 5 years after
starting PD (C-statistic¼ 0.81–0.92).
Conclusions. EPS risk estimates are lower when calculated us-
ing competing risk of death analyses. A patient’s estimated risk
of EPS is country-speciﬁc and can be predicted using age, pri-
mary renal disease and duration of PD.
Keywords: age, encapsulating peritoneal sclerosis, peritoneal
dialysis, peritoneal membrane, prognosis
INTRODUCTION
Encapsulating peritoneal sclerosis (EPS) is a serious, uncom-
mon condition predominantly affecting patients exposed to
peritoneal dialysis (PD). Due to the strong association between
EPS and longer periods of exposure to PD treatment [1–3], an
important management question for patients is when the risk of
future EPS becomes sufficiently high to justify switching to hae-
modialysis (HD) to mitigate this risk. Appropriate decisions re-
quire accurate assessment of the risk of EPS, including an
accurate estimation of the impact of exposure time of PD on
EPS risk.
For some patients, even if the risk of EPS is thought to be
high, it may still be relatively small in comparison to the risk of
death. The challenge for safe and effective management is esti-
mating when the risk of future EPS becomes sufficiently high to
justify switching to HD, as there may be significant disruption
to the patient’s quality of life and little length of life advantage.
Appropriate clinical judgements and shared decisions with
patients require an accurate risk assessment of EPS informed by
a patient’s clinical indicators rather than population-based
associations between incidence and exposure to PD treatment.
As death prevents the opportunity to develop EPS, death can
be considered a competing risk to EPS. Analyses using method-
ology that does not appropriately incorporate competing events
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have been shown to overestimate the probability of occurrence
of the event of interest [4–6]. Examples of competing risks in
nephrology include time until peritonitis episode with compet-
ing events of technique failure/death/transplantation [7], end-
stage kidney disease for diabetes patients with the competing
event of death [8] and cause-specific mortality (cardiac death
versus other causes of death) [9, 10].
When identifying risk factors in a competing risks situation,
standard (cause-specific) survival methodology can be applied
to estimate relative risks that reflect the direct association be-
tween the risk factor and a specific outcome. However, as the
assumption of independent censoring can no longer be justi-
fied, competing risks methodology and the cumulative inci-
dence function [11] are required to provide unbiased risk
estimates. Competing risks analysis adjusts for the rate and risk
of the competing events when estimating the absolute risk of
the event of interest. Thus the risk of EPS for any given predic-
tor variable (e.g. older age) would appreciably overestimate the
true risk if that predictor variable was also associated with an in-
creased risk of death and that competing risk was not taken into
account.
To our knowledge, there has been no analysis of the inci-
dence of EPS using a competing risks approach, such that previ-
ous risk estimates may have been misleadingly high.
Furthermore, the prior identification of risk factors for EPS
based on analyses that did not correctly account for the pres-
ence of competing risks may have been misleading. We sought
to determine unbiased probabilities of EPS occurrence and
death and consider the prognostic factors that enable identifica-
tion of high-risk patients.
MATERIALS AND METHODS
Population
Data were extracted from two large registries, the Australia
and New Zealand Dialysis and Transplant (ANZDATA)
Registry and the Scottish Renal Registry (SRR). The ANZDATA
data comprised all PD patients who started PD between January
1990 and December 2010 and were followed-up until October
2012. SRR data comprised PD patients who started PD between
January 2000 and January 2008 with follow-up until April 2012
[10]. For both data sources, patients who started PD before they
turned 18 years of age were excluded.
Follow-up started on the patient’s first date on PD and
ended in the event of EPS, death or administrative censoring on
October 2012 for ANZDATA and April 2012 for SRR. Follow-
up continued whether or not a patient was still receiving PD, as
EPS frequently occurs following PD cessation [12].
Outcome and prognostic factors
In the ANZDATA registry, the EPS diagnosis was taken
from comorbidity, cause of death or cause of PD cessation
records as recorded by nephrologists from the contributing
units, based on International Society for Peritoneal Dialysis
(ISPD) criteria or, prior to that, those from Rigby and Hawley
[1]. In the SRR, the EPS diagnosis was actively sought, with
questionnaires sent to each centre and searching SRR data
reported in hospital discharge statistics. Medical records were
examined to ensure the ISPD criteria were met and excluded if
another potential cause was present or if they lacked radiologi-
cal or pathological confirmation.
Factors common to both data sets included age, gender, pri-
mary renal disease (as a surrogate for comorbidity as full infor-
mation was not available in the SRR), diabetes status and
cumulative exposure to PD in years. Primary renal disease was
dichotomized as those considered to have a low risk of death
(polycystic disease, isolated glomerulonephritis, chronic pyelo-
nephritis) and those with a high risk of death (all others, includ-
ing uncertain aetiology).
Statistical methods
Quantification of the risk of EPS. Non-parametric esti-
mates of the risk of EPS with cumulative time on PD were cal-
culated using a Kaplan–Meier estimate and cumulative
incidence function with death as a competing risk [13]. Direct
comparisons of the estimates are presented.
Prognostic factors for EPS. Both univariable and multivari-
able models were fitted to investigate associations between the
candidate prognostic factors and EPS. Flexible parametric mod-
els [14] using splines with three degrees of freedom to model
the baseline log cumulative hazard were developed and both
cause-specific hazard ratios (HRs) and subdistribution HRs es-
timated with a proportional hazards model. Non-linear associa-
tions were investigated using fractional polynomial terms and
all first-order interactions tested for including registry with
prognostic factors. Due to the disparity in prevalence of EPS, all
analyses were stratified by registry. Proportional subdistribu-
tion hazards were assessed with time-dependent effects.
Predictability of EPS. The potential prognostic ability of a
model predicting the risk of EPS was investigated through the
development of prognostic models in PD patients at the start of
treatment and 3 and 5 years after starting treatment.
Multivariable flexible parametric models were used, assuming
proportional subdistribution hazards, and stratified by registry,
varying the baseline hazard functions between registries while
retaining equal prognostic factor effects. The discrimination of
the models was determined using Harrell’s C-statistic. The
prognostic models were used to predict cumulative incidence
function estimates for EPS and death separately over time for a
high-risk and a low-risk patient group (age <40 years, low-risk
primary renal disease versus age 60–80 years, high-risk primary
renal disease) in patients still on PD.
All analyses used StataMP version 14 (StataCorp, College
Station, TX, USA). The level of statistical significance was set at
0.05.
RESULTS
Characteristics and clinical outcomes
The analysis comprised 17 396 patients: 16 162 from the
ANZDATA registry and 1234 patients from the SRR. Patient
demographic characteristics (Table 1) illustrate systematic dif-
ferences between the two populations; ANZDATA patients are
older with a higher rate of diabetes mellitus.
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The most common outcome in both studies was death, oc-
curring in 54.6% of ANZDATA patients and 52.3% of SRR
patients. EPS was a rare event, with only 65 (0.4%) cases ob-
served in the ANZDATA population and 34 (2.8%) in the SRR
population. A total of 43.4% (ANZDATA) and 39.2% (SRR)
remained on PD at 3 years, with 25.1% (ANZDATA) and
17.7% (SRR) at 5 years.
Comparing those patients who experienced EPS or death,
patients who experienced EPS were significantly more likely to
be younger and less likely to have either diabetes or a high-risk
renal diagnosis (Table 1). There were also notably longer me-
dian follow-up times and median duration of PD treatment for
those patients who developed EPS.
Quantification of the risk of EPS
The difference in the risk of EPS according to whether com-
peting risks were ignored (Kaplan–Meier) or accounted for (cu-
mulative incidence function) are shown in Figure 1. The
Kaplan–Meier curve derived markedly higher EPS risk esti-
mates than those derived accounting for competing risks, par-
ticularly after 4 years of PD treatment.
Prognostic factors for EPS
An increasing duration of PD was consistently associated
with an increasing risk of EPS when using the duration of PD as
the timescale, with a non-linear relationship suggested by
graphing estimates from standard survival analysis and a linear
one in the competing risks estimates (Figure 1). The same pat-
tern was evident when the duration of PD was tested as a covar-
iate in models using calendar time as the timescale (Table 2). In
these models, age was not significantly associated with EPS risk
in the standard survival analysis, but older age was associated
with a lower EPS risk in the competing risks analysis {subdistri-
bution HR 0.77 [95% confidence interval (CI) 0.68–0.88]}. Sex,
diabetes and high-risk primary renal disease were not signifi-
cantly associated with the risk of developing EPS. The effects ofTa
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FIGURE 1: Risk of EPS calculated using ‘standard’ and competing
risks approaches. The ﬁgure shows the non-parametric estimates of
EPS risk over cumulative PD exposure. The standard approach, us-
ing the Kaplan–Meier estimate, is shown by the broken line. The
competing risks approach, using the cumulative incidence function
estimate, is shown by the solid line.
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the prognostic factors were consistent across data sets, with no
evidence of an interaction.
Predictability of EPS
Three competing risks prognostic models predicting the risk
of EPS in PD patients at baseline and 3 and 5 years after the
start of PD are presented (Table 3). The time on PD introduced
an immortal time bias, so only age and primary renal disease
were considered in the baseline model. The C-statistics demon-
strated good discrimination for the baseline model in both the
ANZDATA (0.74) and SRR (0.79) populations. Inclusion of the
duration of PD exposure in the 3- and 5-year models improved
the prognostic ability of the models further, with C-statistics be-
tween 0.81 and 0.92, but inclusion of whether a patient was cur-
rently on PDmade no significant difference.
The potential utility of prognostic models for predicting in-
dividual EPS risk is demonstrated in Figures 2 and 3. Using the
baseline risk of the ANZDATA population (Figure 2) for
patients currently on PD, the probability of developing EPS was
negligible both at the start of PD and 5 years after the start of
PD for patients at high risk of death (ages 60–80 years, high-
risk primary renal diagnosis). For the patients at low risk of
death (age<40 years, low-risk primary renal diagnosis), the
risk of EPS was larger. If the baseline risk of the SRR population
was used (Figure 3), then the risk of EPS remained low com-
pared with the risk of death in those patients at high risk of
death, but became highly significant for patients at low risk of
death 5 years after the start of PD. Plots for patients 3 years after
the start of PD demonstrated intermediate risks between those
in the graphs for patients at the start of PD and 5 years after the
start (Supplementary data, Figure S1).
DISCUSSION
We have demonstrated that estimation of EPS risk is strongly
affected by death as a competing event and that statistical tech-
niques need to take this into account. For example, neither age
nor primary renal disease appeared to be directly associated
with the rate of EPS occurrence, but they were significant pre-
dictors when death was incorporated as a competing event.
Combining age, primary renal diagnosis (as a surrogate for co-
morbidity) and the duration of PD accounted for the majority
of the variability in EPS when allowing for death in the model.
Previous studies using models to estimate EPS risk have all
used techniques such as the Kaplan–Meier estimator or the cu-
mulative hazard [3, 10, 15, 16]. A fundamental assumption of
these models is that EPS will eventually occur in all patients, a
hypothetical scenario with no deaths. The effect is overestima-
tion of the risk of EPS, known as competing risks bias [17]. The
longer the follow-up and the greater the risk of competing
events, the greater the overestimation. Estimates for EPS were
strongly affected because, relative to the common competing
event of death, EPS occurrence was rare.
Not accounting for the competing risks appropriately has
likely led to the perception that the risk of EPS rises exponen-
tially with the duration of PD [3, 15, 18]. We have clearly dem-
onstrated that, when death is appropriately accounted for, this
is not the case. This was illustrated both visually, with cumula-
tive incidence function curves using the duration of PD as a
Table 2. Prognostic factors for EPS in patients starting PD
Standard analysis Competing risks analysis
Unadjusted Adjusted Unadjusted Adjusted
HR (95% CI) P-value HR (95% CI) P-value SHR (95% CI) P-value SHR (95% CI) P-value
Age (10 years) 0.932 (0.81–1.07) 0.324 0.899 (0.78–1.04) 0.146 0.724 (0.64–0.82) <0.001 0.771 (0.68–0.88) <0.001
Sex, male 0.896 (0.59–1.35) 0.602 1.024 (0.67–1.56) 0.911 0.871 (0.59–1.29) 0.491 1.171 (0.78–1.75) 0.442
Diabetes 0.935 (0.58–1.51) 0.784 1.319 (0.75–2.33) 0.338 0.500 (0.31–0.80) 0.004 0.854 (0.49–1.48) 0.574
High-risk PRD 0.770 (0.51–1.17) 0.223 0.707 (0.43–1.16) 0.170 0.465 (0.31–0.69) <0.001 0.714 (0.44–1.15) 0.166
Duration of PD (per year)a 1.168 (1.11–1.23)
0.985 (0.98–0.99)
<0.001 1.172 (1.11–1.23)
0.984 (0.98–0.99)
<0.001 1.448 (1.35–1.55) <0.001 1.415 (1.32–1.52) <0.001
HR, cause-speciﬁc hazard ratio; PRD, primary renal disease; SHR, subdistribution hazard ratio.
aFractional polynomial terms with powers 2 and 3 were selected to model the non-linearity of the duration of PD in the standard analysis.
Table 3. Prognostic models for 5-year risk of EPS stratiﬁed by dataset
Baseline 3 years 5 years
Participants in cohort, n % 17 396 (100) 11 126 (64.0) 6975 (40.1)
EPS, n 99 79 55
SHR (95% CI) SHR (95% CI) SHR (95% CI)
Age (10 years) 0.756 (0.67–0.88) 0.739 (0.64–0.86) 0.733 (0.61–0.87)
High-risk PRD 0.585 (0.39–0.88) 0.474 (0.29–0.76) 0.381 (0.21–0.71)
Duration of PD (per year) – 11.707 (4.36–31.43) 4.994 (2.78–8.98)
ANZ SRR ANZ SRR ANZ SRR
Discrimination C-statistic (95% CI) 0.74 (0.65–0.82) 0.79 (0.70–0.88) 0.87 (0.81–0.94) 0.81 (0.75–0.88) 0.87 (0.80–0.94) 0.92 (0.89–0.96)
PRD, primary renal disease; SHR, subdistribution hazard ratio.
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timescale (Figure 1), and numerically, testing for a non-linear
effect of PD duration in the survival models (Table 2).
One of the unexpected findings of this study was the magni-
tude of the difference in the risk of EPS between the
ANZDATA and SRR data sets. Potential reasons include ascer-
tainment bias, as the SRR data set identified EPS cases via ques-
tionnaires and follow-up phone calls to all centres. In
comparison, the ANZDATA cases were identified through
FIGURE 2: ANZDATA risks of EPS and death over time. Cumulative risk of EPS (black area) and death (grey area) over time in patient
groups at low risk of death (left-hand column) and high risk of death (right-hand column) demonstrated for patients starting PD (top) and
patients 5 years after starting PD (bottom).
FIGURE 3: SSR risks of EPS and death over time. Cumulative risk of EPS (black area) and death (grey area) over time in patient groups at low
risk of death (left-hand column) and high risk of death (right-hand column) demonstrated for patients starting PD (top) and patients 5 years
after starting PD (bottom).
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routinely returned registry codes, whichmay have been less reli-
able than specific study data. However, it may have in part also
represented true differences in EPS risk between the different
populations, possibly via differences in peritonitis, genetics and
dialysate usage [19], as estimates of risk between countries have
varied (e.g. between 0.6% and 6.6% for patients on PD for >5
years) and may vary within a country over time [20, 21].
Registry reports for some of the period included suggest a simi-
lar rate, but there are no data available on genotypes or dialysate
usage. We overcame this disparity by stratifying the analysis to
enable the underlying risk of EPS to differ between the registries
while keeping the effect of the prognostic factors on the out-
come stable.
The clinical impact of this analysis is that both the individual
risk of death for a patient and the current level of EPS risk in
the local PD population need to be considered when discussing
whether to switch to HD to avoid EPS (illustrated in Figures 2
and 3). For all patients at high risk of death, the risk of EPS is
low (right-hand column of both figures), even 5 years after the
start of PD. The impact of different population risks of EPS
becomes relevant in those patients at low risk of death, as illus-
trated by patients 5 years after the start of PD (bottom left plot,
Figures 2 and 3). For this group in the ANZDATA population,
the risk of EPS, while higher than in other groups, remained of
debatable significance. For the corresponding group in the SRR
population, the risk of EPS was greater than the risk of death,
emphasizing the need for accurate national data collection to
inform clinical risk prediction.
For patients at high risk of death/low risk of EPS, a switch to
HD will take the patient off their preferred modality, with the
attendant disruption to their quality of life, when the likely out-
come is death whether or not the patient is switched.
Furthermore, the risk of EPS spikes immediately after PD has
stopped [22], so attempting to avoid EPS in this scenario could
perversely increase the risk of EPS prior to death. For the small
proportion of patients still on PD several years after starting
with a low risk of death/high risk of EPS, and where transplan-
tation is not imminent, a switch to HD may be appropriate,
subject to an informed discussion with the patient.
A prognostic model that informed clinicians and patients of
the absolute risks of EPS and death could help in the shared
decision-making process. This was not possible due to the dif-
ference in baseline risk between the data sets, which would need
to be defined for the population in which the prognostic model
will be used. However, in the models developed, the duration of
PD, age and primary renal disease were strongly predictive of
EPS, demonstrating that a prognostic model could be success-
ful, and the presence of competing risks bias demonstrates the
need for a competing risks model to ensure accurate calibration.
Previous studies have identified other risk factors that may help
to identify patients at high risk of EPS, including impaired so-
dium sieving, poor ultrafiltration or decreased osmotic conduc-
tance to glucose, peritonitis episodes, dialysate inflammatory
cytokine levels, exposure to non-biocompatible dialysis sol-
utions and dialysate glucose exposure [10, 15, 22–26]. The pre-
dictive performance of the reported models indicates that
adding further biomarkers to the prognostic model is unlikely
to improve the prediction of EPS in a meaningful way, as a
C-statistic of 0.92 (albeit on internal validation) is unlikely to
improve dramatically for the overall population.
Limitations of this study include the fact that the model in-
cluded a limited number of EPS events. There were some sim-
plifications, such as not accounting for transplantation or
switches to HD, which may have affected the risks of EPS and
death differentially. This was mainly due to not having the ap-
propriate information from the registry data sets. However,
with more granular data, model extensions could involve multi-
state modelling to incorporate wait-listing for transplantation,
having a transplant and being on HD as distinct states or joint
modelling of cumulative time on PD. We were unable to in-
clude more predictors due to the limited prognostic factors
common to both data sets and we were unable to determine a
generalizable estimate of the baseline risk of EPS, as discussed
previously. One other caveat is that there is no direct evidence
that switching from PD to HD will mitigate the risk of EPS, al-
though the strong association between duration of PD and EPS
risk is likely to lead to this practice anyway.
In conclusion, the estimated risk of EPS can be substantially
biased if death is treated as censored. When appropriately
accounted for, the effect of duration of PD on EPS risk is linear,
highly significant and, when combined with age and primary
renal disease, provides accurate discrimination for EPS risk af-
ter prolonged periods of PD. There is a large apparent differ-
ence in risk between Scotland and ANZ, highlighting the need
for robust data collection to ascertain the true risk in individual
countries.
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